Skip to content

OsteoArthritis and Therapy for Sleep

Efficacy of Scalable CBT for Insomnia in Older Adults With Osteoarthritis Pain

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02946957
Acronym
OATS
Enrollment
327
Registered
2016-10-27
Start date
2016-10-31
Completion date
2020-11-30
Last updated
2020-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia Related to Osteoarthritis Pain

Brief summary

Osteoarthritis (OA) pain affects 50 percent of older adults, more than half of whom also experience significant sleep disturbance. This randomized trial will determine whether a telephone-based cognitive behavioral treatment targeting insomnia in older adults with chronic severe OA-related insomnia and pain results in substantially greater reductions in insomnia severity and in related improvements in pain, fatigue, mood, quality of life and healthcare costs compared to telephone-delivered education (attention control) about insomnia. The trial will test an intervention that if demonstrated to have long term efficacy is scalable and has the potential for wide-scale deployment in healthcare systems.

Detailed description

Twenty-five percent of older adults experience significant osteoarthritis (OA)-related comorbid sleep disturbance. Insomnia is associated with substantial negative effects on function, mood, and medical resource utilization. Cognitive behavioral therapy for insomnia (CBT-I) is evidence based and has been shown to be efficacious in populations with a variety of comorbid conditions including OA-related chronic pain. However, in-person CBT interventions are unlikely to be widely deployable in healthcare systems. Telephone delivery has the advantage of giving patients access to personalized, efficacious CBT-I interventions from home, increasing generalizability, and outreach to minority, rural, and other underserved populations. Older (60+ yrs) primary care patients across Washington State will be screened for severe persistent OA-related insomnia and pain. Two hundred and seventy patients will be randomized to either CBT-I or an education only attention control (EOC). Each treatment will consist of six 20-30 minute telephone-based sessions over an eight week period. Pre-treatment, post-treatment (2 months and 12 month) assessments will include measures of sleep, pain, fatigue, mood, and quality of life. A cost effectiveness evaluation of the intervention will also be conducted. The proposed research will determine if telephone CBT-I improves OA insomnia and associated outcomes in a state-wide primary care population of older adults, and inform policy decisions about widespread dissemination of telephone CBT-I in this and related patient populations.

Interventions

Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.

Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.

Sponsors

Kaiser Permanente
CollaboratorOTHER
University of Washington
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 60+ with one or more health care visits for OA in the prior 3 years * Score of ≥6 on 4-item ISI at first screening and ≥11 on full ISI at second screening * Score of ≥9 on two items from the Brief Pain Inventory (BPI) asking about average pain intensity in the past 2 weeks (0-10 scale) and activity interference due to pain (0-10 scale) at first and second screening

Exclusion criteria

* Not continuously enrolled at Group Health Cooperative for at least one year * Prior diagnosis of a primary sleep disorder: sleep apnea with an AHI/RDI score of 15+ or current use of a CPAP machine; periodic leg movement disorder; restless leg syndrome; sleep-wake cycle disturbance; or rapid eye movement behavior disorder * Diagnosis in the medical record of: rheumatoid arthritis, terminal disease, being considered for major surgery, active chemotherapy or radiation for cancer, or inpatient treatment for congestive heart failure within the previous 6 months * Diagnosis of dementia, use of acetylcholinesterase inhibitor and/or memantine for cognitive impairment, or cognitive impairment (\>6 on the Short Orientation-Memory-Concentration Test) * Hearing or speech impairment sufficient to preclude participation in a telephone intervention

Design outcomes

Primary

MeasureTime frameDescription
Insomnia Severity Index (ISI)12 months post baselineA 7-item questionnaire that is a global measure of perceived insomnia severity. Items use a 5-point scale for total scores of 0-28, with \>15 considered moderate severity.

Secondary

MeasureTime frameDescription
Pittsburgh Sleep Quality Index (PSQI)2 months post baselineSelf-rating of overall sleep quality and disturbances using 7 sleep. components. PSQI global \>5 is highly sensitive and specific for distinguishing good and poor sleepers.
Brief Pain Inventory-short form (BPI-sf)2 months post baselineA questionnaire to assess pain intensity and interference with activities. The BPI-sf rates pain intensity (4 items) and interference (7 items) from 0 to 10 and is validated for use in clinical trials with OA pain patients.
Flinders Fatigue Scale (FFS)2 months post baselineA 7-item self-report questionnaire to measure fatigue level in a variety of situations.
Patient Health Questionnaire (PHQ-8)2 months post baseline4-point scale rates frequency of occurrence of 8 depressive symptoms.
Sleep Hygiene Index (SHI)2 months post baselineA 13-item scale that rates how often participants engage in specific sleep hygiene related behaviors, including continued adherence to CBT-I recommendations over time.
Insomnia Severity Index (ISI)2 months post baselineA 7-item questionnaire that is a global measure of perceived insomnia severity.Items use a 5-point scale for total scores of 0-28, with \>15 considered moderate severity.
Western Ontario and McMaster Universities Arthritis Index (WOMAC)2 months post baselineA 24-item questionnaire rating pain, stiffness, and physical functioning in everyday activities. It is the most widely used condition-specific quality of life measure for arthritis cost-effectiveness studies.
Use of sleep and pain medicationsBaseline through 24 monthsNSAID, analgesic, sedative, and anti-depressant medication use.
Outpatient visitsBaseline through 24 monthsThe number of visits for OA, for sleep problems, and for visits irrespective of associated diagnosis.
Health care costsBaseline through 24 monthsThe Group Health cost database will be used to estimate costs (from study entry to 24 months post enrollment) of ambulatory healthcare for all conditions, arthritis and sleep problems, and inpatient care.
EuroQoL 5D (EQ-5D)2 months post baselineRates health status on five dimensions and overall health status from 0 to 100. The most widely used measure in clinical trials assessing general quality of life of OA patients.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026